Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPO1 | O14980 | 19/20 | 0.84 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.53 |
| ▸ | RANBP1 | P43487 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1336052 | 1.00 | XPO1 (0.84) | XPO1ESR1HTR1APTGS1PTGS2 | |
| SCHEMBL1336049 | 1.00 | XPO1 (0.84) | XPO1ESR1HTR1APTGS1PTGS2 | |
| SCHEMBL12128278 | 0.94 | XPO1 (0.78) | XPO1ESR1HTR1APTGS1PTGS2 | |
| SCHEMBL1336175 | 0.94 | XPO1 (0.78) | XPO1ESR1HTR1APTGS1PTGS2 | |
| SCHEMBL1335998 | 0.94 | XPO1 (0.78) | XPO1ESR1HTR1APTGS1PTGS2 | |
| SCHEMBL1336173 | 0.94 | XPO1 (0.78) | XPO1ESR1HTR1APTGS1PTGS2 | |
| SCHEMBL1336003 | 0.94 | XPO1 (0.78) | XPO1ESR1HTR1APTGS1PTGS2 | |
| SCHEMBL1336170 | 0.94 | XPO1 (0.78) | XPO1ESR1HTR1APTGS1PTGS2 | |
| SCHEMBL1336000 | 0.94 | XPO1 (0.78) | XPO1ESR1HTR1APTGS1PTGS2 | |
| SCHEMBL23133387 | 0.93 | XPO1 (0.77) | XPO1ESR1HTR1APTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11318120-B2 | Nuclear transport modulators and uses thereof | BIOGEN MA INC. (US) | 2022-05-03 | — | — | US | claimed |
| US-20210251968-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | BIOGEN MA INC. (US) | 2021-08-19 | — | — | US | claimed |
| US-10202366-B2 | Methods of promoting wound healing using CRM1 inhibitors | Karyopharm Therapeutics Inc. (US) | 2019-02-12 | — | — | US | claimed |
| US-20140155370-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2014-06-05 | — | — | US | claimed |
| US-20110275607-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2011-11-10 | — | — | US | claimed |
| US-12577225-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260062391-A1 | HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12291508-B2 | Hydrazide containing nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2025-05-06 | — | — | US | disclosed |
| US-20250059158-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS AGENT | 2025-02-20 | — | — | US | disclosed |
| EP-3663291-B1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2024-12-18 | — | — | EP | disclosed |
| US-20240376114-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS AGENT | 2024-11-14 | — | — | US | disclosed |
| US-20240279188-A1 | HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS AGENT | 2024-08-22 | — | — | US | disclosed |
| EP-2736887-A1 | HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics, Inc. (US) | 2014-06-04 | — | — | EP | disclosed |
| EP-2736883-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics, Inc. (US) | 2014-06-04 | — | — | EP | disclosed |
| US-20130317031-A1 | Nuclear Transport Modulators And Uses Thereof | Karyopharm Therapeutics Inc. (US) | 2013-11-28 | — | — | US | disclosed |
| WO-2013170068-A2 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| US-8513230-B2 | Nuclear transport modulators and uses thereof | KARYOPHARM THERAPEUTICS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| WO-2013019561-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2013-02-07 | — | — | WO | disclosed |
| WO-2013019548-A1 | HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2013-02-07 | — | — | WO | disclosed |
| US-20110275607-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210251968-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, XPO5, XPOT | XPO1 1/4885ESR1 2059/4885HTR1A 3253/4885 |
| US-20240376114-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, XPO5, XPOT | XPO1 1/4885ESR1 2299/4885HTR1A 4175/4885 |
| US-10202366-B2 | Methods of promoting wound healing using CRM1 inhibitors | XPO1, XPA, ERCC2 | XPO1 1/4885ESR1 3566/4885HTR1A 3986/4885 |
| US-20140155370-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, NXF1, XPOT | XPO1 1/4885ESR1 2480/4885HTR1A 4615/4885 |
| US-20110275607-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, NXF1, XPOT | XPO1 1/4885ESR1 2480/4885HTR1A 4615/4885 |
| US-12577225-B2 | Nuclear transport modulators and uses thereof | XPO1, XPOT, CSE1L | XPO1 1/4885ESR1 1766/4885HTR1A 2889/4885 |
| US-20130317031-A1 | Nuclear Transport Modulators And Uses Thereof | XPO1, XPO5, XPOT | XPO1 1/4885ESR1 2235/4885HTR1A 4175/4885 |
| US-11318120-B2 | Nuclear transport modulators and uses thereof | XPO1, XPO5, XPOT | XPO1 1/4885ESR1 2059/4885HTR1A 3253/4885 |
| US-20260062391-A1 | HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | SLC8A1, SLC9A1, SLC8B1 | XPO1 15/4885ESR1 2825/4885HTR1A 3120/4885 |
| US-20240279188-A1 | HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, KPNA1, ABCB11 | XPO1 1/4885ESR1 4071/4885HTR1A 2892/4885 |
| US-20250059158-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, XPO5, XPOT | XPO1 1/4885ESR1 2333/4885HTR1A 4187/4885 |
| US-12291508-B2 | Hydrazide containing nuclear transport modulators and uses thereof | XPO1, KPNA1, ABCB11 | XPO1 1/4885ESR1 4071/4885HTR1A 2892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.